Recent Updates
Recently added Catalysts
MYO Positive Sentiment

Myomo to Report Fourth Quarter 2024 Financial Results on March 10

Monday, March 3, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Myomo, Inc. has announced that it will report its financial results for the fourth quarter and full year ending December 31, 2024, on March 10, 2025. The company specializes in wearable medical robotics aimed at improving the functionality of individuals with neurological disorders and upper-limb paralysis. This upcoming report reflects Myomo's commitment to transparency with its investors.
Price reaction · baseline $5.02 (2025-03-03T16:18:00.000Z) · hit during market hours · clean, no other MYO news in the window
day 0 close · peak
-4.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Myomo is actively reporting its financial results.
  • The company focuses on innovative solutions for neurological disorders.
  • The announcement indicates transparency and engagement with stakeholders.

Full Press Release Details

BURLINGTON, Mass. (March 3, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on March 10, 2025. Read more .

Frequently Asked Questions

When will Myomo report its Q4 2024 financial results?

Myomo will report its financial results on March 10, 2025.

What is Myomo's focus area?

Myomo specializes in wearable medical robotics for neurological disorders.

What is the significance of Myomo's announcement?

The announcement reflects Myomo's commitment to transparency with stakeholders.

ShareAdd on Google
Tags: MYO Viatris Investor Conferences Healthcare Myomo financial results wearable robotics neurological disorders upper-limb paralysis
Last updated: Mar 3, 2025

Biotech snapshot

Cash runway
$13M liquidity · $1M/mo burn
~20 mo
Low dilution risk